MY121743A - Progestin therapy with controlled bleeding - Google Patents

Progestin therapy with controlled bleeding

Info

Publication number
MY121743A
MY121743A MYPI98004790A MYPI9804790A MY121743A MY 121743 A MY121743 A MY 121743A MY PI98004790 A MYPI98004790 A MY PI98004790A MY PI9804790 A MYPI9804790 A MY PI9804790A MY 121743 A MY121743 A MY 121743A
Authority
MY
Malaysia
Prior art keywords
progestin
water
present
teaches
progestin therapy
Prior art date
Application number
MYPI98004790A
Other languages
English (en)
Inventor
William J Bologna
Howard L Levine
Dominique De Ziegler
Original Assignee
Columbia Lab Bermuda Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia Lab Bermuda Ltd filed Critical Columbia Lab Bermuda Ltd
Publication of MY121743A publication Critical patent/MY121743A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
MYPI98004790A 1997-10-21 1998-10-21 Progestin therapy with controlled bleeding MY121743A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6348597P 1997-10-21 1997-10-21
US09/170,326 US6306914B1 (en) 1997-10-21 1998-10-13 Progestin therapy for maintaining amenorrhea

Publications (1)

Publication Number Publication Date
MY121743A true MY121743A (en) 2006-02-28

Family

ID=26743461

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI98004790A MY121743A (en) 1997-10-21 1998-10-21 Progestin therapy with controlled bleeding

Country Status (19)

Country Link
US (3) US6306914B1 (cg-RX-API-DMAC7.html)
EP (1) EP1032399A1 (cg-RX-API-DMAC7.html)
JP (1) JP2003535015A (cg-RX-API-DMAC7.html)
KR (1) KR100581308B1 (cg-RX-API-DMAC7.html)
CN (1) CN1147301C (cg-RX-API-DMAC7.html)
AR (1) AR013981A1 (cg-RX-API-DMAC7.html)
AU (1) AU742166C (cg-RX-API-DMAC7.html)
BR (1) BR9813262A (cg-RX-API-DMAC7.html)
CA (2) CA2649671A1 (cg-RX-API-DMAC7.html)
HU (1) HUP0004133A3 (cg-RX-API-DMAC7.html)
IL (1) IL135742A (cg-RX-API-DMAC7.html)
MX (1) MXPA00003972A (cg-RX-API-DMAC7.html)
MY (1) MY121743A (cg-RX-API-DMAC7.html)
NO (1) NO326856B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ504066A (cg-RX-API-DMAC7.html)
PE (1) PE121799A1 (cg-RX-API-DMAC7.html)
RO (1) RO121319B1 (cg-RX-API-DMAC7.html)
RU (2) RU2261099C2 (cg-RX-API-DMAC7.html)
WO (1) WO1999020282A1 (cg-RX-API-DMAC7.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127129A (en) * 1998-11-18 2004-06-01 Ferring Bv Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared
US20040191276A1 (en) * 1999-11-30 2004-09-30 Cutispharma, Inc. Compositions and kits for compounding pharmaceuticals
US8425892B2 (en) * 2001-10-29 2013-04-23 Columbia Laboratories, Inc. Extended, controlled-release pharmaceutical compositions using charged polymers
NZ591627A (en) * 2001-12-05 2012-09-28 Teva Womens Health Inc Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
AU2003239869A1 (en) * 2002-05-23 2003-12-12 Michael Holick Use of a parathyroid hormone peptide analogs for the treatment of vaginal atrophy
AU2003297534A1 (en) * 2002-12-24 2004-07-22 Ovion, Inc. Contraceptive device and delivery system
US7772219B2 (en) * 2003-05-02 2010-08-10 Teva Women's Health, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
PL1635843T3 (pl) * 2003-06-25 2009-06-30 Bayer Schering Pharma Ag Hormonalna terapia zastępcza i leczenie depresji obejmujące dienogest
CA2771944A1 (en) * 2003-07-16 2005-01-27 Teva Women's Health, Inc. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
EP1761231A1 (en) * 2004-06-07 2007-03-14 Duramed Pharmaceuticals, Inc. Dispenser for progestin used for acute and maintenance treatment of dub
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
WO2007076144A2 (en) * 2005-12-27 2007-07-05 Duramed Pharmaceuticals, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
WO2007085020A2 (en) * 2006-01-20 2007-07-26 Pear Tree Pharmaceuticals, Inc. Method of treating atrophic vaginitis
US8235047B2 (en) 2006-03-30 2012-08-07 Conceptus, Inc. Methods and devices for deployment into a lumen
KR20090029237A (ko) * 2006-06-02 2009-03-20 피어 트리 파머슈티칼스 인코포레이티드 위축성 질염을 치료하는 방법
GB0616444D0 (en) * 2006-08-18 2006-09-27 Reckitt Benckiser Nv Detergent composition
EP2112923A1 (en) 2007-01-22 2009-11-04 Targacept Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
US8828981B2 (en) 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
ES2648640T3 (es) 2008-02-04 2018-01-04 Ferring B.V. Anillos intravaginales monolíticos que comprenden progesterona y métodos de fabricación y usos de los mismos
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
KR20170040209A (ko) 2014-07-29 2017-04-12 쎄러퓨틱스엠디, 인코퍼레이티드 경피 크림
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
RU2697369C1 (ru) * 2018-12-21 2019-08-13 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Способ дифференциальной диагностики функциональной гипоталамической аменореи на фоне стресса и энергетического дефицита
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
CN113288865B (zh) * 2021-06-28 2022-03-08 浙江仙琚制药股份有限公司 一种黄体酮阴道凝胶剂的制备方法
CN114983929A (zh) * 2022-05-16 2022-09-02 安徽万邦医药科技股份有限公司 一种稳定的黄体酮缓释凝胶及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0830004B2 (ja) 1983-11-14 1996-03-27 コロンビア ラボラトリーズ インコーポレイテッド 生物接着性組成物およびそれにより治療する方法
USD345211S (en) 1992-04-06 1994-03-15 Columbia Laboratories, Inc. Dispensing vial for feminine hygiene products
US5543150A (en) * 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
USD375352S (en) 1994-03-14 1996-11-05 Columbia Laboratories, Inc. Dispensing vial for feminine hygiene products

Also Published As

Publication number Publication date
RU2330667C2 (ru) 2008-08-10
NZ504066A (en) 2002-11-26
US6593317B1 (en) 2003-07-15
HUP0004133A3 (en) 2001-09-28
KR100581308B1 (ko) 2006-05-22
RU2261099C2 (ru) 2005-09-27
RU2005101612A (ru) 2006-07-10
IL135742A (en) 2004-09-27
CA2649671A1 (en) 1999-04-29
WO1999020282A1 (en) 1999-04-29
MXPA00003972A (es) 2004-04-21
CA2307615A1 (en) 1999-04-29
AU742166C (en) 2005-07-14
AU1191499A (en) 1999-05-10
CN1147301C (zh) 2004-04-28
NO20002084L (no) 2000-06-21
NO326856B1 (no) 2009-03-02
AU742166B2 (en) 2001-12-20
US6306914B1 (en) 2001-10-23
HUP0004133A2 (hu) 2001-05-28
KR20010031299A (ko) 2001-04-16
US20010031747A1 (en) 2001-10-18
CN1282250A (zh) 2001-01-31
AR013981A1 (es) 2001-01-31
BR9813262A (pt) 2000-08-22
RO121319B1 (ro) 2007-03-30
JP2003535015A (ja) 2003-11-25
PE121799A1 (es) 1999-12-17
EP1032399A1 (en) 2000-09-06
NO20002084D0 (no) 2000-04-19
IL135742A0 (en) 2001-05-20

Similar Documents

Publication Publication Date Title
MXPA00003972A (es) Terapia de progestina con sangrado controlado.
LT96027A (en) Use of a cross-linked polycarboxylic polymer and progesterone for manufacture of medicinal preparations
BR9709934A (pt) Kit de terapia de reposição hormonal e/ou contraceptivo uso de unidades de dosagem diária consistindo essecialmente de um progestogênio e processo de preparação de um sistema de liberação de droga
RU2000112650A (ru) Прогестинотерапия с регулируемым кровотечением
IL122432A0 (en) Transdermal patch for preventing ovulation
ZA958434B (en) Use and composition of an anti-sexually transmitted diseases formulation
PT100323A (pt) Dispositivo para a reducao das sensacoes durante a administracao iontoforetica de um agente terapeutico
ES2090714T3 (es) Matriz de vidrio de carbohidrato para la liberacion prolongada de un agente terapeutico.
EG20401A (en) Process for preparing of veterinary composition for the treatment of gastric acid related deseases in animals
GR3019124T3 (en) Solid matrix system for transdermal drug delivery.
PL324552A1 (en) Plaster for pecutaneous administration of hormones
ZA985863B (en) Transdermal therapeutic system
MX9702162A (es) Procedimiento para hacer unidades de dosis mediante granulacion en humedo.
HU9401849D0 (en) Transdermally administrated system containing acetylsalicylic acid for thrombosis therapy and cancer prophylaxis
MX9804395A (es) Proceso y equipo anticonceptivos para mamiferos hembra, que comprenden una combinacion de gestageno y estrogeno.
AU6821687A (en) System for delivering drug with enhanced bioacceptability
NZ332215A (en) Transdermally administered dextromethorphan as antitussive agent
ES366313A1 (es) Procedimiento de preparacion de composiciones moldeadas controladoras de la ovulacion del estro en bovinos.
GEP20043253B (en) Progestin Therapy with Controlled Bleeding
ZA945431B (en) Use of benzydamine in the treatment of pathological conditions caused by TNF
JPS55149212A (en) Gradually releasing preparation of methotrexate
Kishimoto et al. ADFR Treatment for Osteoporosis
UA95691C2 (ru) Фармацевтическая вагинальная композиция и ее применение